Clinical Trial Update: Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study [Phase 2]

View source ↗

Summary

Phase 2 trial investigating anlotinib combined with docetaxel in non-driver mutation non-squamous non-small cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Yongchang Zhang | Conditions: Non-Squamous Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN